2024-2029 Animal Health Market Analysis, Competitive Landscape and Global Forecasts: Accelerated Rate of Change and Regulatory Uncertainty - Performance, Capabilities, Goals and Strategies of Leading Suppliers

2024-2029 Animal Health Market Analysis, Competitive Landscape and Global Forecasts: Accelerated Rate of Change and Regulatory Uncertainty - Performance, Capabilities, Goals and Strategies of Leading Suppliers

Will the industry consolidate, decentralize, or undergo a bimodal transformation?

How will the current trends affect the major market segments?

Which companies will enter the market and which will not survive?

This new report analyzes strategies, marketing tactics and technological know-how of the world’s leading animal health companies, including:

Five-year forecasts for:

Major market segments
Key geographic regions

Assessment of major U.S. and international trends with potentially significant impact on the animal health industry during the next five years, including discussion of such issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics and other technologies.

Company Profiles

Bayer

Rising demand for collars
Focusing on parasiticides and anti-infectives
Strong position in parasiticides
Animal health R&D
Worldwide marketing network
Emerging markets
Re-registering existing products
Present structure
Diverse businesses
Challenged by animal disease outbreaks
Europe's premier research organization
Animal health R&D
Crop science segment
Monsanto acquisition
Supervisory board

Boehringer Ingelheim

Sales and growth
Animal health is one of the major pillars
Swine vaccine Ingelvac circoflex
Merial animal health
U.S. animal health market position
Promoting Eqvalan line
Seeking to reinforce position in livestock market
Strategies supported by collaborations
Merial R&D programs
Collaborative efforts
Porcine Reproductive and Respiratory Syndrome (PRRS)
Decentralized R&D

Ceva

Sales, growth and R&D investment
Biomune, Phylaxia and French sites
Hatcher automation and in-ovo vaccination
India acquisition
Brazil--important strategic market
Merial swine vaccines acquisition

Elanco

Strong technological base
Fermentation and chemical synthesis
Strong base in antibiotics and anticoccidials
Expiration of patents caused restructuring
US marketing
Lilly Japan
Focused marketing strategies
Well-established relationship with customers
Multi-disciplinary business with diverse product portfolio
In the midst of strategic decisions
Stepping up efforts to curtail time to market
Could divest animal health
Changed product mix
Strategic collaborations
Broadening portfolio of companion animal medicines
Hard look at bottom line

Merck

Sales and growth
Extensive know-how in animal health
Sphereon technology
Expanding worldwide poultry business
Poultry biological research laboratories
Segmented poultry-product line
Mitigated generic competition
R&D productivity improving
Patents, economies of scale, and powerful intellectual base

Phibro

Sales and growth
Extensive portfolio of antibiotics and antibacterials
Sales force, sales offices and distribution network
Animal health R&D facilities

Virbac

Sales and growth
Eli Lilly dog parasiticides acquisition
Product portfolio
Formulation know-how
Waltham nutrition products
Reorganized European distribution
Decentralized approach for food-producing animals
Benefitting from new companion animal products
Focusing on niche markets
Seeking expansion in the U.S.

Zoetis

Majority of revenue from production animals
Largest market share in the industry
Poultry and swine revenue declining
Scale allows to use own sales force in emerging markets
Management continues cost-cutting efforts
Reassessing manufacturing infrastructure
Market-leading position in emerging markets
Leading share in Asia-Pacific, Canada and Latin America
Fragmented customer base
Leading position in fastest-growing markets

Contains 110 pages and 6 tables

Please note: The delivery time for the electronic version of this report is between 1-3 business days to allow the preparation of an updated version prior to dispatch.